Pictet Asset Management Holding SA Acquires 12,358 Shares of GRAIL, Inc. $GRAL

Pictet Asset Management Holding SA lifted its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 30.2% during the first quarter, HoldingsChannel reports. The firm owned 53,284 shares of the company’s stock after acquiring an additional 12,358 shares during the quarter. Pictet Asset Management Holding SA’s holdings in GRAIL were worth $2,526,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Royal Bank of Canada grew its position in shares of GRAIL by 17.7% in the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock valued at $2,250,000 after purchasing an additional 13,264 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares in the last quarter. NewEdge Advisors LLC raised its holdings in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after buying an additional 1,401 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in GRAIL by 37.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock valued at $2,362,000 after buying an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of GRAIL by 115.7% in the second quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock valued at $4,090,000 after buying an additional 42,675 shares during the period.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Negative Sentiment: Multiple law firms announced or reiterated class-action claims against GRAIL, saying investors who bought shares between May 13, 2025 and February 19, 2026 may have losses stemming from alleged misrepresentations about trial results and the February 20, 2026 stock collapse. Article Title
• Negative Sentiment: Several firms reminded shareholders of the August 4, 2026 lead-plaintiff deadline, keeping investor attention focused on litigation risk and the possibility of further legal costs or reputational damage for GRAIL. Article Title
• Neutral Sentiment: Additional firms issued near-identical investor alerts and lawsuit reminders, reinforcing the same legal overhang but not adding new operational or financial developments for the company. Article Title

Insider Buying and Selling at GRAIL

In other GRAIL news, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $6,165,219.84. Following the sale, the chief executive officer directly owned 518,582 shares in the company, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Aaron Freidin sold 45,806 shares of the business’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the sale, the chief financial officer directly owned 260,669 shares in the company, valued at $13,012,596.48. This trade represents a 14.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 232,464 shares of company stock valued at $11,621,242 over the last quarter. 1.83% of the stock is currently owned by corporate insiders.

GRAIL Price Performance

Shares of GRAL opened at $69.11 on Monday. The stock has a market capitalization of $2.97 billion, a P/E ratio of -6.66 and a beta of 3.22. GRAIL, Inc. has a twelve month low of $29.95 and a twelve month high of $118.84. The company has a 50 day moving average of $62.41 and a 200-day moving average of $70.49.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47. The business had revenue of $40.78 million for the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. On average, sell-side analysts anticipate that GRAIL, Inc. will post -10.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Piper Sandler increased their price objective on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Mizuho initiated coverage on shares of GRAIL in a research note on Friday, April 10th. They issued a “neutral” rating and a $58.00 target price for the company. TD Cowen increased their target price on GRAIL from $65.00 to $69.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Guggenheim lowered their target price on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a report on Monday, March 30th. Finally, Robert W. Baird set a $70.00 price target on GRAIL in a research note on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $67.00.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.